Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
Open accessThe DOI matches its Crossref record; 68 of the 69 references it cites were found in a registry or an index.
Abstract
Variable regions 1 and 2 (V1/V2) of human immunodeficiency virus-1 (HIV-1) gp120 envelope glycoprotein are critical for viral evasion of antibody neutralization, and are themselves protected by extraordinary sequence diversity and N-linked glycosylation. Human antibodies such as PG9 nonetheless engage V1/V2 and neutralize 80% of HIV-1 isolates. Here we report the structure of V1/V2 in complex with PG9. V1/V2 forms a four-stranded β-sheet domain, in which sequence diversity and glycosylation are largely segregated to strand-connecting loops. PG9 recognition involves electrostatic, sequence-independent and glycan interactions: the latter account for over half the interactive surface but are of sufficiently weak affinity to avoid autoreactivity. The structures of V1/V2-directed antibodies CH04 and PGT145 indicate that they share a common mode of glycan penetration by extended anionic loops. In addition to structurally defining V1/V2, the results thus identify a paradigm of antibody recognition for highly glycosylated antigens, which-with PG9-involves a site of vulnerability comprising just two glycans and a strand.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Sometimes, such protective glycosylation can become so dense that it generates unique clustered epitopes recognized by speci fi c antibodies, such as that seen on the surface of the HIV virion (507 -509, 594).”
From Biological roles of glycans (2017) · cites this paper as [507]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · cited 1×
“and a molecular replacement solution for the 1FD6-ZM109 data set consisting of two unbound PG9 Fab molecules per asymmetric unit was obtained using PHASE”
The PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,715
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 9,984
Nicholls, A., Sharp, K. A., & Honig, B. (1991) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340110407 · Cited by 5,240
PHENIX : building new software for automated crystallographic structure determination
Adams, P. D., Grosse-Kunstleve, R. W., Hung, L.-W., Ioerger, T. R., McCoy, A. J., Moriarty, N. W., Read, R. J., Sacchettini, J. C., Sauter, N. K., & Terwilliger, T. C. (2002) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444902016657 · Cited by 4,361
MolProbity: all-atom contacts and structure validation for proteins and nucleic acids
Davis, I. W., Leaver-Fay, A., Chen, V. B., Block, J. N., Kapral, G. J., Wang, X., Murray, L. W., Arendall, W. B., Snoeyink, J., Richardson, J. S., et al. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm216 · Cited by 3,896
The Anatomy and Taxonomy of Protein Structure
Richardson, J. S. (1981) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60520-3 · Cited by 3,375
Research works printed but not linked: 2
- Zolla-Pazner S V2-reactive antibodies in RV144 vaccinees’ plasma AIDS Res Hum Retroviruses 27 A-21 2011
- Otwinowski, Z. & Minor, W. in Methods Enzymol. Vol. 276, 307–326 (Academic Press, 1997)
Cited by
Items 601–700 of 831
Germline-targeting HIV immunogen induces cross-neutralizing antibodies in outbred macaques
Mishra, N., Liang, B., Roark, R. S., Ghosh, A. R., Callaghan, S., Lee, W.-H., Li, X., Vo, A. L., Avillion, G., Chowdhury, R. R., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.03.012 · Cited by 14
Self-citationRao, P. G., Lambert, G. S., & Upadhyay, C. (2023) · Journal of Virology · doi:10.1128/jvi.00710-23 · Cited by 8
“structurally conserved region targeted by some of the most potent HIV-1 bNAbs (14-18).”
BackgroundWang, S., Chan, K.-W., Wei, D., Ma, X., Liu, S., Hu, G., Park, S., Pan, R., Gu, Y., Nazzari, A. F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48514-8 · Cited by 8
“Nonetheless, remarkable progress has been made in isolating human monoclonal antibodies (mAbs) from HIV-infected patients with high breadth and potency, as well as the structural de fi nition of the recognition of these antibodies on the HIV-1 Env spike 6,13 – 16 .”
Self-citationA Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen
Vijayan, A., García‐Arriaza, J., Raman, S. C., Conesa, J. J., Chichón, F. J., Santiago, C. A., Sorzano, C. Ó. S., Carrascosa, J. L., & Estéban, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133595 · Cited by 11
Thenin-Houssier, S., Roch, E., Samleerat, T., Moreau, T., Chaillon, A., Moreau, A., Barin, F., & Braibant, M. (2012) · Journal of General Virology · doi:10.1099/vir.0.042614-0 · Cited by 9
“…the most remarkable breadth since they neutralize 70–80 % of circulating HIV-1 isolates, suggesting that the targeted epitope(s) are highly conserved among variants of the entire group M. Recently, the structure of the V1/V2 region in complex with PG9 was reported (McLellan et al., 2011).”
BackgroundMethodInfluentialGirard, M. P., Picot, V., Longuet, C., & Nabel, G. J. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.02.068 · Cited by 11
Self-citationRinge, R. P., & Bhattacharya, J. (2013) · Therapeutic Advances in Vaccines · doi:10.1177/2051013613494534 · Cited by 13
HIV-Specific Antibody Responses in HIV-Infected Patients: From a Monoclonal to a Polyclonal View
Gallerano, D., Cabauatan, C. R., Sibanda, E., & Valenta, R. (2015) · International Archives of Allergy and Immunology · doi:10.1159/000438484 · Cited by 10
Li, C., Jin, W., Du, T., Wu, B., Liu, Y., Shattock, R. J., & Hu, Q. (2014) · Virologica Sinica · doi:10.1007/s12250-014-3525-8 · Cited by 9
Broadly Neutralizing Antibodies and the Promise of Universal Vaccines: Where are we Now?
Hefferon, K. L. (2013) · Immunotherapy · doi:10.2217/imt.13.150 · Cited by 9
Das, S., Boliar, S., Mitra, N. K., Samal, S., Bansal, M., Koff, W. C., & Chakrabarti, B. K. (2016) · Retrovirology · doi:10.1186/s12977-016-0312-7 · Cited by 10
“However, structural evidences have shown that N-linked glycosylation either clustered or dispersed along with strand-connecting loops are involved in recognition of glycan-directed conformational antibodies [39, 40, 44] Although, N156 and N160 in JRFL and JRCSF are conserved, there are some differences in strand C bet…”
BackgroundSelf-citationExtracellular Matrix Proteins Mediate HIV-1 gp120 Interactions with α4β7
Plotnik, D. A., Guo, W., Cleveland, B., von Haller, P. D., Eng, J. K., Guttman, M., Lee, K. K., Arthos, J. A., & Hu, S.-L. (2017) · Journal of Virology · doi:10.1128/jvi.01005-17 · Cited by 9
Self-citationOpening dynamics of HIV-1 gp120 upon receptor binding is dictated by a key hydrophobic core
Da, L., & Lin, M. (2019) · Physical Chemistry Chemical Physics · doi:10.1039/c9cp04613e · Cited by 9
Peterhoff, D., Thalhauser, S., Neckermann, P., Barbey, C., Straub, K., Nazet, J., Merkl, R., Längst, G., Breunig, M., & Wagner, R. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.10.007 · Cited by 13
Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers
Bontjer, I., Melchers, M., Tong, T., van Montfort, T., Eggink, D., Montefiori, D. C., Olson, W. C., Moore, J. P., Binley, J. Μ., Berkhout, B., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067484 · Cited by 8
Utachee, P., Isarangkura-na-ayuthaya, P., Tokunaga, K., Ikuta, K., Takeda, N., & Kameoka, M. (2014) · Retrovirology · doi:10.1186/1742-4690-11-32 · Cited by 9
“Although the structure of the V2 region of Env gp120 derived from subtype C viruses is already determined [64], that of CRF01_AE has not been determined; therefore, we consider that it is important to solve the protein structure of AE-Env gp120 in order to design an effective vaccine antigen against CRF01_AE viruses.”
BackgroundHu, G., Liu, J., Roux, K. H., & Taylor, K. A. (2017) · Journal of Virology · doi:10.1128/jvi.00134-17 · Cited by 8
“ligands have been determined by X-ray crystallography (7-15).”
BackgroundHeindel, D. W., Figueroa, D. M., Goff, M., Yengo, C. K., Jan, M., Liu, X., Wang, X., Petrova, M., Zhang, M., Sagar, M., et al. (2024) · iScience · doi:10.1016/j.isci.2024.110390 · Cited by 8
Signal peptide exchange alters HIV-1 envelope antigenicity and immunogenicity
Upadhyay, C., Rao, P. S., Behzadi, M. A., Feyznezhad, R., Lambert, G. S., Kumar, R., Kumar, M., Yang, W., Jiang, X., Luo, C. C., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1476924 · Cited by 7
Self-citationLederhofer, J., Borst, A. J., Nguyen, L., Gillespie, R. A., Williams, C., Walker, E. L., Raab, J. E., Yap, C., Ellis, D., Creanga, A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62339-z · Cited by 9
Mathematical models: A key to understanding HIV envelope interactions?
Magnus, C., Brandenberg, O. F., Rusert, P., Trkola, A., & Regoes, R. R. (2013) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.09.002 · Cited by 8
Isik, G., van Montfort, T., Boot, M., Jiménez, V. C., Kootstra, N. A., & Sanders, R. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060126 · Cited by 8
‘Immunization during ART and ATI for HIV-1 vaccine discovery/development’
Stamatatos, L. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000817 · Cited by 9
Vukovich, M. J., Shiakolas, A. R., Lindenberger, J. J., Richardson, R. A., Bass, L. E., Barr, M., Liu, Y., Go, E. P., Park, C. S., May, A. J., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1012499 · Cited by 8
Self-citation(2026) · doi:10.1073/pnas.2532810123 · Cited by 8
Self-citationYang, Z., Li, J., Liu, Q., Yuan, T., Zhang, Y., Chen, L.-Q., Lou, Q., Sun, Z., Ying, H., Xu, J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126428 · Cited by 8
Self-citationGene therapy as a vaccine for HIV-1
Berkhout, B., & Sanders, R. W. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.707177 · Cited by 10
Display of the HIV envelope protein at the yeast cell surface for immunogen development
Mathew, E., Hong, Z., Connelly, S. M., Sullivan, M. A., Brewer, M. G., Piepenbrink, M. S., Kobie, J. J., Dewhurst, S., & Dumont, M. E. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205756 · Cited by 9
Farzani, T. A., Chov, A., & Herschhorn, A. (2020) · STAR Protocols · doi:10.1016/j.xpro.2020.100209 · Cited by 11
“…spike have been the subject of intensive research investigations (Bar et al., 2016; Flemming et al., 2018; Harris et al. 2020; Herschhorn et al., 2011, 2014, 2016; Hoffmann et al., 2020; McLellan et al., 2011; Pancera et al., 2014; Parrish et al., 2013; Riva et al., 2020; Wrapp et al., 2020).”
BackgroundMucosal Delivery of HIV‐1 Glycoprotein Vaccine Candidate Enabled by Short Carbon Nanotubes
Xu, Y., Jiang, X., Zhou, Z., Ferguson, T., Obliosca, J. M., Luo, C. C., Chan, K., Kong, X., & Tison, C. K. (2022) · Particle & Particle Systems Characterization · doi:10.1002/ppsc.202200011 · Cited by 8
Amos, J. D., Himes, J. E., Armand, L. C., Gurley, T. C., Martinez, D. R., Colvin, L., Beck, K., Overman, R. G., Liao, H., Moody, M. A., et al. (2015) · Journal of Virology · doi:10.1128/jvi.01564-15 · Cited by 9
CXCR4-derived synthetic peptides inducing anti-HIV-1 antibodies
Hashimoto, C., Nomura, W., Narumi, T., Fujino, M., Nakahara, T., Yamamoto, N., Murakami, T., & Tamamura, H. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.09.037 · Cited by 8
Optimal Treatment Strategies for HIV with Antibody Response
Zhou, Y., Yang, K., Zhou, K., & Wang, C. (2014) · Journal of Applied Mathematics · doi:10.1155/2014/685289 · Cited by 8
Su, J., Ji, Y., Wang, Q., Wang, H., Shi, X., Han, X., Zhou, T., Shang, H., & Zhang, L. (2016) · Retrovirology · doi:10.1186/s12977-016-0243-3 · Cited by 8
Self-citationA non-canonical binding interface in the crystal structure of HIV-1 gp120 core in complex with CD4
Duan, L., Zhang, H., Zhao, M., Sun, J., Chen, W.-L., Lin, J., & Liu, X. (2017) · Scientific Reports · doi:10.1038/srep46733 · Cited by 9
Ouyang, Y., Yin, Q., Li, W., Li, Z., Kong, D., Wu, Y., Hong, K., Xing, H. Q., Shao, Y., Jiang, S., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05594-5 · Cited by 9
Devasundaram, S., Rosati, M., Valentin, A., Weiß, S., Itri, V., Trinh, H. V., Bear, J., Chowdhury, B., LaBranche, C. C., Montefiori, D. C., et al. (2020) · Journal of Virology · doi:10.1128/jvi.01193-20 · Cited by 9
Habib, R., Roark, R. S., Li, H., Connell, A. J., Hogarty, M. P., Wagh, K., Wang, S., Marchitto, L., Skelly, A. N., Carey, J. W., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.03.652068 · Cited by 19
Self-citationQuinnan, G. V., Zhang, P., Dong, M., Chen, H., Feng, Y., Lewis, M. G., & Broder, C. C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059803 · Cited by 7
The D Gene in CDR H3 Determines a Public Class of Human Antibodies to SARS-CoV-2
Yuan, M., & Wilson, I. A. (2024) · Vaccines · doi:10.3390/vaccines12050467 · Cited by 9
“The extended CDR H3 of PG9 has a hammerhead shape and penetrates the glycan shield that covers the V1/V2 loops on the apex and interacts with a conserved epitope of the Env trimer [54].”
BackgroundSelf-citationPatterns of amino acid conservation in human and animal immunodeficiency viruses
Voitenko, O. S., Dhroso, A., Feldmann, A., Korkin, D., & Kalinina, O. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw441 · Cited by 8
Lai, J. I., Verma, D., Bailey‐Kellogg, C., & Ackerman, M. E. (2018) · Protein Engineering Design and Selection · doi:10.1093/protein/gzy010 · Cited by 7
“Using a protein peeling algorithm (Gelly et al., 2006; Gelly and de Brevern, 2011), the V1V2 loops were extracted as compact sub-domain protein units, resulting in V1V2 boundaries in concordance with other studies (HxB2 residues 126- 196) (Kayman et al., 1994; McLellan et al., 2011).”
BackgroundMethodInfluentialZhao, J., Song, E., Huang, Y., Yu, A., & Mechref, Y. S. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00587 · Cited by 8
Cohen, Y. Z., Lavine, C. L., Miller, C. A., Jetta, G., Carey, B. R., & Seaman, M. S. (2015) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0135 · Cited by 8
Li, D., Wang, Z., Ren, L., Zhang, J., Feng, G., Hong, K., Hao, Y., Qi, Z., Liang, H., & Shao, Y. (2015) · Archives of Virology · doi:10.1007/s00705-015-2710-x · Cited by 7
“[2], 2G12 [24], 2F5 [24], and 4E10 [26], were identified over a decade ago, while the second-generation of NAbs, such as VRC01-class antibodies [30], PG9/PG16 [19], Electronic supplementary material The online version of this article (doi:10.”
BackgroundImmunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice
Wiehe, K. J., Nicely, N. I., Lockwood, B., Kuraoka, M., Anasti, K. M., Arora, S., Bowman, C. M., Stolarchuk, C., Parks, R., Lloyd, K. E., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1601640 · Cited by 8
“Another group of Abs that bind to V2 at K169 are the V2-glycan broadly neutralizing Abs (bnAbs) (6, 7); these bnAbs bind an *Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710; Department of Medicine, Duke University School of Medicine, Durham, NC 27710; Department of Immunology, Duke U…”
BackgroundSelf-citationWu, N. R., Nicely, N. I., Lee, E. M., Reed, R. K., Watts, B. E., Cai, F., Walkowicz, W. E., Aussedat, B., Jones, J. A., Eaton, A., et al. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1008165 · Cited by 8
Self-citationHessell, A. J., Li, L., Malherbe, D. C., Barnette, P. T., Pandey, S., Sutton, W. F., Spencer, D., Wang, X.-H., Gach, J. S., Hunegnaw, R., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001010 · Cited by 7
On the irrationality of rational design of an HIV vaccine in light of protein intrinsic disorder
Uversky, V. N. (2021) · Archives of Virology · doi:10.1007/s00705-021-04984-5 · Cited by 7
Aljedani, S., Liban, T. J., Tran, K., Phad, G. E., Singh, S., Dubrovskaya, V., Pushparaj, P., Martinez-Murillo, P., Rodarte, J. V., Mileant, A., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009543 · Cited by 8
Self-citationMolecular Recognition of HIV Glycans by Antibodies
Kong, L., Stanfield, R. L., & Wilson, I. A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-8872-9_5 · Cited by 7
Self-citationVadnais, M. L., Criscitiello, M. F., & Smider, V. V. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527699124.ch4 · Cited by 7
Roark, R. S., Habib, R., Gorman, J., Li, H. J., Connell, A. J., Bonsignori, M., Guo, Y., Hogarty, M. P., Olia, A. S., Sowers, K. J., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.11.598384 · Cited by 7
Self-citationHIV Env trimers elicit NHP apex cross-neutralizing antibodies mimicking human bNAbsPreprint
Guenaga, J., Ádori, M., Bale, S., Phulera, S., Zygouras, I., Schleich, F.-A., Dopico, X. C., Agrawal, S., Ota, M., Wilson, R., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.19.677470 · Cited by 7
Self-citationBecerra, J. C., Hitchcock, L., Vu, K., & Gach, J. S. (2024) · Microbial Cell · doi:10.15698/mic2024.07.826 · Cited by 8
Human Immunodeficiency Virus Vaccines
Goepfert, P., & Bansal, A. (2014) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2014.08.004 · Cited by 8
Beretta, M., Migraine, J., Moreau, A., Essat, A., Goujard, C., Chaix, M., Drouin, A., Bouvin-Pley, M., Meyer, L., Barin, F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-73975-4 · Cited by 10
Structural development of the HIV-1 apex-directed PGT145-PGDM1400 antibody lineage
Mason, R. D., Zhang, B., Morano, N. C., Shen, C., McKee, K., Heimann, A., Du, R., Nazzari, A. F., Hodges, S., Kanai, T., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2024.115223 · Cited by 7
“…that insert directly into the Env apex cavity through a beta hairpin and we therefore did not include comparisons to those antibodies in the PG9 4,7,9,49,50 or CAP256-VRC26 10,51,52 classes since they differ more substantially from the PGT145-PGDM1400 class in their specific mode of binding.”
Self-citationSynthetic carbohydrate-based HIV-1 vaccines
Bastida, I., & Fernández‐Tejada, A. (2020) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2020.09.004 · Cited by 6
Zong, G., Toonstra, C., Yang, Q., Zhang, R., & Wang, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212538 · Cited by 6
Self-citationReiche, S., Dwai, Y., Bußmann, B. M., Horn, S., Sieg, M., & Jassoy, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128684 · Cited by 6
“The long CDR3 enables the antibodies to penetrate the glycan shield that covers the viral glycoprotein to attach to the protein surface of the molecule ([29, 30].”
BackgroundReceptor Binding Domain Based HIV Vaccines
Liu, H., Bi, W., Wang, Q., Lu, L., & Jiang, S. (2015) · BioMed Research International · doi:10.1155/2015/594109 · Cited by 7
Ding, C., Patel, D., Ma, Y., Mann, J. F. S., Wu, J., & Gao, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.697683 · Cited by 8
V1/V2 Neutralizing Epitope is Conserved in Divergent Non-M Groups of HIV-1
Morgand, M., Bouvin-Pley, M., Plantier, J., Moreau, A., Alessandri-Gradt, É., Simon, F., Pace, C. S., Pancera, M., Ho, D. D., Poignard, P., et al. (2015) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000854 · Cited by 6
Self-citationToward a Carbohydrate-Based HIV-1 Vaccine
Kong, L., Julien, J., Calarese, D. A., Scanlan, C. N., Lee, H., Rudd, P. M., Wong, C., Dwek, R. A., Burton, D. R., & Wilson, I. A. (2012) · ACS symposium series · doi:10.1021/bk-2012-1102.ch007 · Cited by 8
Self-citationA general solution to broad-spectrum vaccine design for rapidly mutating virusesPreprint
Glanville, J., Ives, S., Bürckert, J.-P., Pettus, C., Peñate, K. R., Hovde, R., Bayless, N. L., Shanghavi, D., Glanville, K., Calgua, E., et al. (2020) · doi:10.21203/rs.3.rs-100459/v1 · Cited by 6
“In recent years, it has been discovered that even rapidly mutating pathogens contain some regions of broadly conserved residues on their surface coat proteins [8-10].”
BackgroundAdjuvants influence the maturation of VRC01-like antibodies during immunization
Knudsen, M. L., Agrawal, P., MacCamy, A. J., Parks, K. R., Gray, M. D., Takushi, B. N., Khechaduri, A., Salladay, K. R., Coler, R. N., LaBranche, C. C., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105473 · Cited by 6
Rahman, M. A., Becerra‐Flores, M., Patskovsky, Y., de Castro, I. S., Bissa, M., Basu, S., Shen, X., Williams, L. D., Sarkis, S., N’Guessan, K. F., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1139402 · Cited by 5
“In complex with neutralizing mAbs (e.g. PG9 (49)), V1/V2 conforms to a b-sheet domain (Figure 1A).”
BackgroundA sweet surprise for HIV broadly neutralizing antibodies
Langedijk, J. P. M., & Schuitemaker, H. (2012) · Nature Medicine · doi:10.1038/nm.2993 · Cited by 5
Lai, J. I., Eszterhas, S. K., Brooks, S. A., Guo, C., Zolla‐Pazner, S., Seaman, M. S., Bailey‐Kellogg, C., Griswold, K. E., & Ackerman, M. E. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.03.010 · Cited by 5
Dynesen, L. T., Fernandez, I., Coquin, Y., Delaplace, M., Montange, T., Njouom, R., Bilounga-Ndongo, C., Rey, F. A., Antoine Gessain, A., Backović, M., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011339 · Cited by 5
“It is possible that certain loop-specific nAbs bind several protomers, as described for HIV- and Ebola-specific nAbs [34, 35].”
BackgroundQi, Y., Zhang, S., Wang, K., Ding, H., Zhang, Z., Anang, S., Nguyen, H. T., Kappes, J. C., Sodroski, J., & Mao, Y. (2025) · Communications Biology · doi:10.1038/s42003-025-07852-z · Cited by 10
“Such heterogeneitycoulddiminishthegenerationoref fi cacy of V2 quaternary bNAbs, which bind the Env trimer apex in an asymmetric manner dependent on the glycans at Asn 156 and Asn 160 37,39,58,59 .”
Doran, R. C., Morales, J. F., To, B., Morin, T. J., Theolis, R., Jr., O’Rourke, S. M., Yu, B., Mesa, K. A., & Berman, P. W. (2014) · Molecular Immunology · doi:10.1016/j.molimm.2014.06.025 · Cited by 5
Structure and Design of Broadly-Neutralizing Antibodies Against HIV
Ryu, S. E., & Hendrickson, W. A. (2012) · Molecules and Cells · doi:10.1007/s10059-012-0104-4 · Cited by 5
“Although broadly neutralizing antibodies that target the V1/V2 and glycan have also been found in AIDS patients (McLellan et al., 2011), most broadly neutralizing antibodies recognize the conserved CD4 binding site (Chen et al., 2009; Zhou et al., 2007; 2010).”
BackgroundResultXiang, S.-H. (2014) · Current HIV Research · doi:10.2174/1570162x113116660053 · Cited by 5
“Pancera M, McLellan JS, Wu X, et al. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.”
BackgroundInfluentialAntibody recognition of HIV and dengue glycoproteins
Krauss, I. J. (2016) · Glycobiology · doi:10.1093/glycob/cww031 · Cited by 5
“…making contact near the trimer apex (Julien, Lee, et al. 2013), likely with twoMan5GlcNAc glycans from N160 of neighboring gp120 monomers, as well as with a sialylated complex or hybrid glycan (Pancera et al. 2013) at N173 or the spatially close position N156 (Figure 4A) (McLellan et al. 2011).”
BackgroundKernel-based logistic regression model for protein sequence without vectorialization
Fong, Y., Datta, S., Georgiev, I. S., Kwong, P. D., & Tomaras, G. D. (2014) · Biostatistics · doi:10.1093/biostatistics/kxu056 · Cited by 5
Self-citationBenjelloun, F., Oruc, Z., Thielens, N. M., Verrier, B., Champier, G., Vincent, N., Rochereau, N., Girard, A., Jospin, F., Chanut, B., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600309 · Cited by 8
Pauthner, M. G., & Hangartner, L. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_221 · Cited by 6
Immunogenicity Evaluation of N-Glycans Recognized by HIV Broadly Neutralizing Antibodies
Shivatare, S. S., Cheng, T.-J. R., Cheng, Y., Shivatare, V. S., Tsai, T.-I., Chuang, H.-Y., Wu, C., & Wong, C. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00375 · Cited by 5
D’Antona, A. M., Lee, J. M., Zhang, M., Friedman, C., He, T., Mosyak, L., Bennett, E. M., Lin, L., Silverman, M., Cometa, F., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031931 · Cited by 5
Harnessing the protective potential of HIV-1 neutralizing antibodies
Smith, S. A., & Derdeyn, C. A. (2016) · F1000Research · doi:10.12688/f1000research.7254.1 · Cited by 5
Haryadi, R., Chan, K. F., Lin, P. C., Tan, Y. L., Wan, C., Shahreel, W., Tay, S. J., Nguyen‐Khuong, T., Walsh, I., & Song, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-73722-z · Cited by 5
“PG9 penetrate the glycan shield through its long CDR3 region, fitting precisely between two N -glycans to access the protein backbone on the V1/V2 region 44 .”
BackgroundYousefpour, P., Ghosh, A. R., Chawla, H., Yeung, R., Gregory, J. R., Si, K., Remba, T. K., Rodrigues, K. A., Melo, M. B., Dye, J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.07.036 · Cited by 4
“26,27 These features represent native-like trimeric compositions.”
Self-citationN-Glycans modulate tilting of HIV-1 envelope glycoprotein
Shehata, M., Casalino, L., Duquette, M., Chen, S., Flaherty, A., Waller, P. M., Villa, E., & Amaro, R. E. (2026) · Nature Communications · doi:10.1038/s41467-026-71874-2 · Cited by 12
An HIV-1 Envelope Glycoprotein Trimer with an Embedded IL-21 Domain Activates Human B Cells
Isik, G., Chung, N. P. Y., van Montfort, T., Menis, S., Matthews, K., Schief, W. R., Moore, J. P., & Sanders, R. W. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067309 · Cited by 4
Self-citationChávez, R. A. R., Boyt, D., Schwery, N., Han, C., Wu, L. J., & Haim, H. (2022) · Journal of Virology · doi:10.1128/jvi.00406-22 · Cited by 5
A site of vulnerability at V3 crown defined by HIV-1 bNAb M4008_N1
Chan, K.-W., Luo, C. C., Lü, H., Wu, X., & Kong, X. (2021) · Nature Communications · doi:10.1038/s41467-021-26846-z · Cited by 4
Antibodies: Computer-Aided Prediction of Structure and Design of Function
Sevy, A. M., & Meiler, J. (2015) · ASM Press eBooks · doi:10.1128/9781555817411.ch10 · Cited by 4
Stanfield, R. L., & Wilson, I. A. (2015) · ASM Press eBooks · doi:10.1128/9781555817411.ch3 · Cited by 4
Self-citationVaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1
Hioe, C. E., Liu, X., Banin, A. N., Heindel, D. W., Klingler, J., Rao, P. G., Luo, C. C., Jiang, X., Pandey, S., Ordonez, T., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1271686 · Cited by 4
“We further evaluated whether neutralization was dependent on N160 and its glycan, which are critical for recognition by PG9 and other V2 apex bNAbs (22, 23, 42).”
BackgroundSelf-citationRole of surface glycans in enveloped RNA virus infections: A structural perspective
Pandey, B., Srividhya, S., Chatterjee, A., & Prasad, V. M. (2023) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26636 · Cited by 3
Sequence-Conserved and Antibody-Accessible Sites in the V1V2 Domain of HIV-1 gp120 Envelope Protein
Shmelkov, E., Grigoryan, A., Krachmarov, C. P., Abagyan, R. A., & Cardozo, T. J. (2014) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2014.0034 · Cited by 4
“Crystal structures of V1V2 from different viral strains obtained in complex with the broadly neutralizing Abs (BNAbs) PG9 and PG16 showed that this domain indeed forms a conserved fourstranded b-sheet fold in a Greek-key topology.(12,13) The crystallographic structure of the gp140 trimer affirmed that the same fold is…”
Backgroundvan Montfort, T., Thomas, A. A. M., Krawczyk, P. M., Berkhout, B., Sanders, R. W., & Paxton, W. A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402344 · Cited by 4
Putative role of Tat–Env interaction in HIV infection
Poon, S., Moscoso, C. G., Li, X., Kan, E., Sun, Y., Kolatkar, P. R., Vahlne, A. G., Srivastava, I. K., Barnett, S. W., & Cheng, R. H. (2013) · AIDS · doi:10.1097/01.aids.0000432453.60733.b2 · Cited by 4
“To date, available structures for gp120 subunit have truncations in V1, V2 and/or V3 loops, are usually complexed with CD4 D1/D2 (sCD4) and stabilized by a coreceptor binding site-targeting MAb Fab fragment [8,42,55], while a recent structure shows V1/V2 transplanted onto a protein scaffold [56].”
BackgroundTargeting Glycans of HIV Envelope Glycoproteins for Vaccine Design
Behrens, A., Seabright, G. E., & Crispin, M. (2017) · Royal Society of Chemistry eBooks · doi:10.1039/9781782623823-00300 · Cited by 5
Mesa, K. A., Yu, B., Wrin, T., Petropoulos, C. J., Pogson, G. H., Alexander, D. L., Perez, G., O’Rourke, S. M., Sinangil, F., Robinson, J., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0213409 · Cited by 4
SHAW, A. R., & Feinberg, M. B. (2013) · Elsevier eBooks · doi:10.1016/b978-0-7234-3691-1.00103-3 · Cited by 5
“However, it remains unclear whether and how such potent, broadly neutralizing antibodies might be elicited in humans vaccinated with defined HIV immunogens.(64) This challenge represents the fundamental goal of the next stage of HIV vaccine development efforts.”
BackgroundAbility of nucleoside-modified mRNA to encode HIV-1 envelope trimer nanoparticlesPreprint
Mu, Z., Wiehe, K. J., Saunders, K. O., Henderson, R. C., Cain, D. W., Parks, R., Martik, D., Mansouri, K., Edwards, R. J., Newman, A., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.09.455714 · Cited by 4
“…immunogenic regions occluded by adding glycans (CH848 10.17DT with D230N, H289N, P291S) in addition to adding the E169K mutation, which is critical to interactions with V2-glycan bnAbs, including trimer-specific bnAb PGT145 (Doria-Rose et al., 2012; Lee et al., 2017; McLellan et al., 2011).”
BackgroundSelf-citationN-Glycans Modulate HIV-1 Env Conformational PlasticityPreprint
Shehata, M., Casalino, L., Duquette, M., Chen, S., Flaherty, A., Villa, E., & Amaro, R. E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.26.645577 · Cited by 4
Metadata
- Authors
- McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., O’Dell, S., Patel, N., Shahzad-ul-Hussan, S., Yang, Y., Zhang, B., Zhou, T., Zhu, J., Boyington, J. C., Chuang, G.-Y., Diwanji, D., Georgiev, I., Do Kwon, Y., Lee, D., Louder, M. K., Moquin, S., Schmidt, S. D., Yang, Z.-Y., Bonsignori, M., Crump, J. A., Kapiga, S. H., Sam, N. E., Haynes, B. F., Burton, D. R., Koff, W. C., Walker, L. M., Phogat, S., Wyatt, R., Orwenyo, J., Wang, L.-X., Arthos, J., Bewley, C. A., Mascola, J. R., Nabel, G. J., Schief, W. R., Ward, A. B., Wilson, I. A., & Kwong, P. D.
- Affiliations
- National Institutes of Health (US)
- University of Washington (US)
- Scripps Research Institute (US)
- Duke University (US)
- Tumaini University (TZ)
- International AIDS Vaccine Initiative (US)
- University of Maryland, Baltimore (US)
- Corresponding author
- Kwong, Peter D.
- ORCID
- McLellan, Jason S.
- Pancera, Marie
- Carrico, Chris
- Gorman, Jason
- Julien, Jean-Philippe
- Khayat, Reza
- Louder, Robert
- Patel, Nikita
- Yang, Yongping
- Zhang, Baoshan
- Zhou, Tongqing
- Zhu, Jiang
- Boyington, Jeffrey C.
- Chuang, Gwo-Yu
- Diwanji, Devan
- Georgiev, Ivelin
- Louder, Mark K.
- Moquin, Stephanie
- Schmidt, Stephen D.
- Bonsignori, Mattia
- Crump, John A.
- Kapiga, Saidi H.
- Haynes, Barton F.
- Burton, Dennis R.
- Koff, Wayne C.
- Walker, Laura M.
- Wyatt, Richard
- Wang, Lai-Xi
- Arthos, James
- Bewley, Carole A.
- Mascola, John R.
- Nabel, Gary J.
- Schief, William R.
- Ward, Andrew B.
- Wilson, Ian A.
- Kwong, Peter D.
- Venue
- Nature
- Published
- 2011-11-23
- Volume
- 480
- Issue
- 7377
- Pages
- 336-343
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3406929
- OpenAlex
- W2122617162
- Cited by
- 830
- References
- 69
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 23 · 2023: 25 · 2022: 36 · 2021: 38 · 2020: 39 · 2019: 52 · 2018: 63 · 2017: 70 · 2016: 64 · 2015: 84 · 2014: 92 · 2013: 120 · 2012: 78
- FWCI
- 36.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DukeSpace (Duke University) (submittedVersion, cc-by-nc-nd)
- Funders
- U.S. Department of Energy (W - 31 - 109 - Eng - 38)
- International AIDS Vaccine Initiative
- Ragon Institute of MGH, MIT and Harvard
- National Institutes of Health
- Office of Science (W-31-109-ENG-38)
- Canadian Institutes of Health Research
- National Institute of Allergy and Infectious Diseases (R01AI033292, R01AI084817)
- National Center for Research Resources (RR017573, P41RR017573)
- Basic Energy Sciences (W-31-109-Eng38)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Physical Sciences › Chemistry › Organic Chemistry › Carbohydrate Chemistry and Synthesis
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- HIV-1 gp120, antibody-antigen complex structure, N-glycosylation, carbohydrate recognition, HIV vaccine development, envelope glycoprotein
- MeSH terms
- Amino Acid Sequence, Antibody Affinity, Antibody Specificity, Antigen-Antibody Complex, Epitopes, Binding Sites, Antibody, Glycopeptides, Glycosylation, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Polysaccharides, HIV Antibodies, HIV-1, HIV Envelope Protein gp120, AIDS Vaccines, Conserved Sequence, Protein Structure, Tertiary, Crystallography, X-Ray, Amino Acid Motifs, Protein Structure, Quaternary, Immune Evasion, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.